Input parameters | Base case value | References |
---|---|---|
Vaccination | Â | Â |
Duration of vaccine protection | Lifetime | Assumption |
Age at Vaccination (years) | 12 | Assumption |
Vaccine Coverage | 100% | Assumption |
Efficacy: HPV-16/18 (both vaccines) | 98.0% | |
HPV-16/18 AS04-adjuvanted Vaccine | Â | Â |
Efficacy: Non-vaccine oncogenic HPV types | Â | Â |
   CIN1 | 47.7% (95% CI: 28.9%, 61.9%) | [51] |
   CIN2+ | 68.4% (95% CI: 45.7%, 82.4%) | [25] |
HPV-6/11/16/18 vaccine Efficacy: Non-vaccine oncogenic HPV types | Â | [27] |
   CIN1 | 23.4% (95% CI: 7.8%, 36.4%) |  |
   CIN2+ | 32.5% (95% CI: 6.0%, 51.9%) |  |
HPV-6/11/16/18 Vaccine Efficacy: HPV 6/11 | 98.0% | [50] |
Screening | Â | Â |
Screening Coverage | Â | [52] |
   Age Range | 18 to 69 years |  |
   Regular (once/ 3 years) | 70% |  |
   Irregular (ages 25, 40, 50) | 18% |  |
   Never | 12% |  |
CIN1 detected (sensitivity) | 42% | |
CIN2/3 detected (sensitivity) | 55% | |
% Positive pap Smear | 5% | |
Cost (2006 CAD) | Â | Â |
HPV-16/18 AS04-adjuvanted vaccine Cost (per dose) | $110.97 | Assumption |
HPV-6/11/16/18 vaccine Cost (per dose) | $110.97 | Assumption |
Genital Warts treatment (per episode) | $207.00 | [44] |
Cytology Test | $57.00 | |
Colposcopy and biopsy | $150.00 | |
CIN1 treatment and follow-up* | $843.00 | |
CIN2/3 treatment and follow-up* | $1 414.00 | |
Cervical cancer stage 1 | $11 915.00 | |
Cervical cancer stage 2 | $18 851.00 | |
Cervical cancer stage 3 | $18 851.00 | |
Cervical cancer stage 4 | $25 759.00 | |
Utility | Â | Â |
No HPV, HPV Infection | 1, 1 | Â |
CIN1 detected | 0.987 | |
CIN2/3 detected | 0.991 | |
Cancer treated | 0.727 | |
Cancer cured | 0.938 | |
Genital Warts | 0.980†| [59] |